Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Taiho Pharmaceutical and Toray Co-Develop Overactive Bladder Agent

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Taiho Pharmaceutical and Toray March 11 started a joint development of beta-3-adrenoceptor agonist TRK-380/TAC-301 to treat overactive bladder. The two are preparing to start a Phase I trial in Japan. The agent works to relax bladder muscle and increase the bladder volume by stimulating the beta-3 adrenoreceptors. The details of the co-development agreement including payment are not disclosed. Taiho has set urology products a development priority. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts